In a First for Biosimulation, GNS Partners with Crowley Center to Model Cancer Trial Data | GenomeWeb

Gene Network Sciences said last week that it has entered into a partnership with the Mary Crowley Medical Research Center that will mark the first use of biosimulation technology in cancer clinical trials.

GNS will use its computational modeling technology to identify biomarkers associated with response in cancer clinical trials — an approach that the Crowley Center is betting will prove more powerful than traditional bioinformatics analysis of microarray and proteomic data.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.